TARCEVA TARCEVA TARCEVA

Dose: 100 mg
Single Dose: 100 (100)
Frequency: 24 hourly
Route: oral
Instructions: For non-small cell PANCREATIC cancer, should be taken at least one hour before or two hours after the ingestion of food.

belongs to Quinazolinamine. It belongs to Epidermal Growth Factor Receptor pharmacological group on the basis of mechanism of action. The Molecular Weight of Erlotinib is 429.90. It is strongly acidic drug and Its pKa is 5.42.

Erlotinib is contraindicated in conditions like Cough,Dyspepsia,Fever,fever,Gastrointestinal perforation,Pulmonary disease.

The severe or irreversible adverse effects of Erlotinib, which give rise to further complications include Skin rashes.Erlotinib produces potentially life-threatening effects which include GI perforation, Interstitial lung disease. which are responsible for the discontinuation of Erlotinib therapy.The symptomatic adverse reactions produced by Erlotinib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Fatigue, Nausea, Vomiting, Anorexia, Diarrhea, Dyspnea, Abdominal pain, Rashes, Stomatitis, Pruritus, Dyspepsia, Cough, Dry skin, Conjunctivitis, Infection, GI bleeding, Keratoconjunctivitis sicca, dyspepsia, Pruritis, GI disturbance, Alopecia.

Erlotinib is primarily indicated in conditions like Metastatic lung cancer, Metastatic pancreatic cancer, Non small cell lung cancer.

Erlotinib is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAtazanavirThis CYP3A4 inhibitor increases levels/toxicity of erlotinibClarithromycinThis CYP3A4 inhibitor increases levels/toxicity of erlotinibErythromycinThis CYP3A4 inhibitor increases levels/toxicity of erlotinibIndinavir (Sulphate)This CYP3A4 inhibitor increases levels/toxicity of erlotinibItraconazoleThis CYP3A4 inhibitor increases levels/toxicity of erlotinibKetoconazoleThis CYP3A4 inhibitor increases levels/toxicity of erlotinibNefazodone (HCl)This CYP3A4 inhibitor increases levels/toxicity of erlotinibNelfinavirThis CYP3A4 inhibitor increases levels/toxicity of erlotinibRifabutinDecreased levels/effect of erlotinibRifampicinDecreased levels/effect of erlotinibRitonavirThis CYP3A4 inhibitor increases levels/toxicity of erlotinibSaquinavirThis CYP3A4 inhibitor increases levels/toxicity of erlotinibSt.Johns Wort ExtractDecreased levels/effect of erlotinibTelithromycinThis CYP3A4 inhibitor increases levels/toxicity of erlotinibTroleandomycinThis CYP3A4 inhibitor increases levels/toxicity of erlotinibVORICONAZOLEVoriconazole may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

asymptomatic increase in Liver transaminase

Drug should not be given to patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Store Below 30°C.

Treatment should continue until disease progression or unacceptable toxicity occurs. In patients who develop an acute onset of new or progressive pulmonary symptoms, such as dyspnea, cough or fever, treatment with Erlotinib should be interrupted pending diagnostic evaluation. If Interstitial Lung Disease (ILD) is diagnosed, Erlotinib should be discontinued and appropriate treatment instituted as necessary. Interrupt or discontinue Erlotinib in patients with dehydration who are at risk for renal failure, in patients with severe bullous, blistering or exfoliative skin conditions, or in patients with acute /worsening ocular disorders.Avoid in pregnancy Caution is advised when Erlotinib is used with antacids, proton pump inhibitors, H2 receptor antagonist